GlassScriptPhysician profile
Mark B Safford
NPI 1013088012
$1,044.15
in general payments reported to CMS, 2019-2025
17 companies · $23.89 in 2025
The $23.89 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $146 · 2021: $65.70 · 2022: $318 · 2023: $210 · 2024: $79.58 · 2025: $23.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $201.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $144.33 | 2022-2023 | Andexxa |
| Portola Pharmaceuticals, LLC | $119.05 | 2020 | |
| Smith+Nephew, INC. | $103.47 | 2024-2025 | Collagenase Santyl |
| Alexion Pharmaceuticals, INC. | $75.14 | 2022-2023 | Ultomiris |
| Abbvie INC. | $71.86 | 2021-2022 | |
| Gilead Sciences, INC. | $67.57 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $48.08 | 2022-2023 | Recarbrio, Zerbaxa, Dificid |
| Mindray Ds USA, INC. | $43.87 | 2022 | |
| Ucb, INC. | $30.51 | 2020-2021 | |
| Melinta Therapeutics, LLC | $28.42 | 2022-2023 | Rezzayo, Orbactiv, Kimyrsa |
| Csl Behring | $26.53 | 2020-2022 | |
| Boston Scientific Corporation | $19.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.65 | 2023 | Xarelto |
| Mylan Specialty L.P. | $18.18 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $14.63 | 2022 | |
| Shionogi INC | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Safford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.